Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Revenue - OtherShares OutstandingShares Outstanding
Ratios

Lyra Therapeutics (LYRA) Leases (2021 - 2025)

Lyra Therapeutics has reported Leases over the past 5 years, most recently at $16.8 million for Q4 2025.

  • Quarterly results put Leases at $16.8 million for Q4 2025, down 15.72% from a year ago — trailing twelve months through Dec 2025 was $16.8 million (down 15.72% YoY), and the annual figure for FY2025 was $16.8 million, down 15.72%.
  • Leases for Q4 2025 was $16.8 million at Lyra Therapeutics, down from $17.6 million in the prior quarter.
  • Over the last five years, Leases for LYRA hit a ceiling of $45.6 million in Q1 2024 and a floor of $608000.0 in Q3 2022.
  • Median Leases over the past 5 years was $4.1 million (2022), compared with a mean of $11.7 million.
  • Biggest five-year swings in Leases: plummeted 61.9% in 2022 and later skyrocketed 2400.05% in 2024.
  • Lyra Therapeutics' Leases stood at $1.4 million in 2021, then soared by 64.06% to $2.2 million in 2022, then skyrocketed by 1394.96% to $33.2 million in 2023, then plummeted by 40.05% to $19.9 million in 2024, then decreased by 15.72% to $16.8 million in 2025.
  • The last three reported values for Leases were $16.8 million (Q4 2025), $17.6 million (Q3 2025), and $18.4 million (Q2 2025) per Business Quant data.